Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BCD-201

Phase 3Small molecule

BCD-201 is one of 36 small molecule programs targeting Melanoma. It is currently in Phase 3.

1

Indications

2

Total Trials

0

Active Trials

35

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Tecentriq

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Roferon-a

CC 5013

Bristol-Myers Squibb

Methylphenidate Hydrochloride

Adjuvant Therapy

FFudan University

Interferon-Alpha-2a

Anti-PD1

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melanoma1 trial

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Unknown status·BBiocad·Phase 3·NCT05986331·366 enrolled

Advanced Malignancies1 trial

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Unknown status·BBiocad·Phase 1·NCT05739006·131 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BCD-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCD-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCD-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBiocad

Related News